Rybka Justyna, Jurczak Wojciech, Giza Agnieszka, Paszkiewicz-Kozik Ewa, Kumiega Beata, Drozd-Sokołowska Joanna, Butrym Aleksandra, Kuliczkowski Kazimierz, Wróbel Tomasz
Department of Hematology, Wroclaw Medical University, Poland.
Department of Hematology, Collegium Medicum, Jagiellonian University, Kraków, Poland.
Adv Clin Exp Med. 2015 Sep-Oct;24(5):783-9. doi: 10.17219/acem/34795.
The treatment of patients with relapsed or refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains challenging. Gemcitabine is a cytidine analog with a wide spectrum of antitumor activity. Gemcitabine treatment is widely used to treat patients with certain solid tumors and relapsed/refractory hematological malignancies. There are several reports indicating that this compound is active in lymphoid malignancies. In patients with relapsed or refractory HL and NHL, gemcitabine has demonstrated efficacy as a single agent and in combination with other cytostatics.
The aim of the study was to analyze the efficacy and toxicity of gemcitabine-based chemotherapy in patients with relapsed or refractory lymphomas.
The study evaluated 68 heavily pretreated patients with relapsed/refractory HL and NHL. The median age of the patients was 36 years. All the patients received gemcitabine-based chemotherapy (gemcitabine monotherapy or gemcitabine in combination with other cytostatics).
The overall response rate was 46%. Complete response was achieved by 21% of the patients and partial response by 25%. Out of those who responded to gemcitabine treatment, 26 patients proceeded to autologous stem cell transplant. Toxicities connected with gemcitabine therapy occurred in 44% of the patients and included grade 3/4 neutropenia, thrombocytopenia and anemia.
The results suggest that gemcitabine-based salvage chemotherapy is effective and well tolerated in patients with relapsed/refractory HL and NHL.
复发或难治性霍奇金淋巴瘤（HL）和非霍奇金淋巴瘤（NHL）患者的治疗仍然具有挑战性。吉西他滨是一种具有广泛抗肿瘤活性的胞苷类似物。吉西他滨治疗广泛用于治疗某些实体瘤和复发/难治性血液系统恶性肿瘤患者。有几份报告表明该化合物在淋巴系统恶性肿瘤中具有活性。在复发或难治性HL和NHL患者中，吉西他滨已证明作为单药及与其他细胞毒性药物联合使用时均有效。
本研究的目的是分析以吉西他滨为基础的化疗对复发或难治性淋巴瘤患者的疗效和毒性。
本研究评估了68例接受过大量预处理的复发/难治性HL和NHL患者。患者的中位年龄为36岁。所有患者均接受以吉西他滨为基础的化疗（吉西他滨单药治疗或吉西他滨与其他细胞毒性药物联合使用）。
总缓解率为46%。21%的患者达到完全缓解，25%的患者达到部分缓解。在对吉西他滨治疗有反应的患者中，26例进行了自体干细胞移植。44%的患者发生了与吉西他滨治疗相关的毒性反应，包括3/4级中性粒细胞减少、血小板减少和贫血。
结果表明，以吉西他滨为基础的挽救性化疗对复发/难治性HL和NHL患者有效且耐受性良好。
